BioMarin Pharma (BMRN) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $57.44 -1.83%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.47), $0.12 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $230.9 million versus the consensus estimate of $189.01 million.
BioMarin Pharma sees FY2015 revenue of $885-915 million, versus the consensus of $880.6 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple (AAPL) Tops Q4 EPS by 11c, Beats on Revenue, Beats on iPhone sales, Misses China
- Upwork Inc. (UPWK) Tops Q3 EPS by 8c; Offer Guidance
- Transocean (RIG) Reports In-Line Q3 EPS, Misses on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
